Mechanism
Central appetite regulation
Appetite is regulated by brain circuits that integrate gut and fat-tissue signals. GLP-1 receptor agonists act on these circuits to reduce subjective hunger and the amount eaten at meals, which is the dominant explanation for chronic weight reduction in clinical trials.
Plain-English explanation
Appetite is regulated by brain circuits that integrate gut and fat-tissue signals. GLP-1 receptor agonists act on these circuits to reduce subjective hunger and the amount eaten at meals, which is the dominant explanation for chronic weight reduction in clinical trials.
Research-level explanation
Convergent evidence from human PET / fMRI studies, ad-libitum eating studies and trial data points to central appetite regulation as the dominant chronic mechanism. GIP and glucagon agonism modulate the same broad circuitry through distinct but overlapping pathways.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| Appetite suppression with GLP-1 RAs is purely psychological. | Functional imaging and PD studies document changes in food-reward circuitry; the effect is biological, not motivational, and is not equivalent to dietary self-control. |
Safety relevance
Psychiatric adverse-event tracking (mood, suicidality signal) sits within this broader pharmacology and is subject to active pharmacovigilance; current EMA and FDA reviews have not established a causal psychiatric safety signal.
- Reduced eating in a trial setting does not establish individual long-term behaviour change.
- Central-effect dominance does not mean peripheral effects (gastric, pancreatic, hepatic) are unimportant for safety.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Peer-reviewed publicationJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site